Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | EIK1004 |
| Synonyms | |
| Therapy Description |
EIK1004 (IMP1707) is a CNS-penetrant PARP1 inhibitor, which potentially decreases growth of homologous recombination deficient tumors (Cancer Res (2025) 85 (8_Supplement_1): 5719). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| EIK1004 | EIK-1004|EIK 1004|IMP1707|IMP 1707|IMP-1707 | PARP-1 Inhibitor 13 | EIK1004 (IMP1707) is a CNS-penetrant PARP1 inhibitor, which potentially decreases growth of homologous recombination deficient tumors (Cancer Res (2025) 85 (8_Supplement_1): 5719). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06907043 | Phase Ib/II | EIK1004 | A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors. (EIK1004-001) | Recruiting | USA | AUS | 1 |